Automated, GMP-ready cell manufacturing (iDEM™) for cell therapies
Mytos offers an automated, GMP-ready cell manufacturing platform called iDEM™ that enables scalable, reproducible production of cell therapies at low cost. It supports partnerships for clinical and commercial manufacturing, reducing costs and scaling capacity efficiently.
Mytos' iDEM™ technology is an automated, GMP-compliant manufacturing platform designed for cell therapies. It allows for scalable and consistent production, significantly reducing costs per dose and minimizing delays associated with hiring and training staff during expansion. The platform supports various engagement models, including CDMO partnerships, integration of BASF reagents, and pilot manufacturing collaborations. The technology is housed within large facilities like CGT Catapult and is positioned for global expansion, aiming to scale regenerative medicine to millions of patients. Mytos also handles all aspects of manufacturing, from process development to regulatory support, making it a comprehensive solution for cell therapy production (Mytos, Result 1).
About Mytos
Mytos is a London-based biotechnology company specializing in automated cell manufacturing solutions for regenerative medicine and cell therapy industries, with a focus on scaling production and reducing costs.
Inquire about this partnering listing
Industry applications
delivered to your inbox.